NCT03158064 2026-01-28
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Memorial Sloan Kettering Cancer Center
N.N. Petrov National Medical Research Center of Oncology
Medical College of Wisconsin
Samsung Medical Center